Integra Cash from 2010 to 2024

IART Stock  USD 21.80  0.09  0.41%   
Integra LifeSciences Cash yearly trend continues to be comparatively stable with very little volatility. Cash is likely to outpace its year average in 2024. Cash is the total amount of money in the form of currency that Integra LifeSciences Holdings has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
1995-09-30
Previous Quarter
215.2 M
Current Value
215.2 M
Quarterly Volatility
137.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Integra LifeSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integra LifeSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 129.7 M, Interest Expense of 53.9 M or Total Revenue of 1.6 B, as well as many indicators such as Price To Sales Ratio of 4.18, Dividend Yield of 3.0E-4 or PTB Ratio of 3.52. Integra financial statements analysis is a perfect complement when working with Integra LifeSciences Valuation or Volatility modules.
  
Check out the analysis of Integra LifeSciences Correlation against competitors.

Latest Integra LifeSciences' Cash Growth Pattern

Below is the plot of the Cash of Integra LifeSciences Holdings over the last few years. Cash refers to the most liquid asset of Integra LifeSciences, which is listed under current asset account on Integra LifeSciences Holdings balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Integra LifeSciences customers. The amounts must be unrestricted with restricted cash listed in a different Integra LifeSciences account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Integra LifeSciences' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Integra LifeSciences' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Integra Cash Regression Statistics

Arithmetic Mean204,308,273
Geometric Mean133,943,423
Coefficient Of Variation79.49
Mean Deviation131,381,031
Median138,838,000
Standard Deviation162,394,835
Sample Variance26372.1T
Range508.9M
R-Value0.78
Mean Square Error11009.3T
R-Squared0.61
Significance0.0006
Slope28,415,810
Total Sum of Squares369209.2T

Integra Cash History

2024290.2 M
2023276.4 M
2022456.7 M
2021513.4 M
2020470.2 M
2019198.9 M
2018138.8 M

Other Fundumenentals of Integra LifeSciences

Integra LifeSciences Cash component correlations

About Integra LifeSciences Financial Statements

Integra LifeSciences shareholders use historical fundamental indicators, such as Cash, to determine how well the company is positioned to perform in the future. Although Integra LifeSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Integra LifeSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Integra LifeSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash276.4 M290.2 M
Cash And Short Term Investments309.1 M324.6 M
Change In Cash-180.3 M-171.2 M
Free Cash Flow73.1 M67.3 M
Begin Period Cash Flow456.7 M479.5 M
Other Cashflows From Financing Activities-9.4 M-9 M
Other Non Cash Items22 M18.7 M
Total Cash From Operating Activities140 M102.4 M
Total Cash From Financing Activities-229.9 M-218.4 M
End Period Cash Flow276.4 M290.2 M
Other Cashflows From Investing Activities(1.00)(1.05)
Total Cashflows From Investing Activities-52.7 M-55.4 M
Cash And Cash Equivalents Changes-53 M-50.3 M
Cash Flows Other Operating15.6 M16.4 M
Free Cash Flow Yield 0.02  0.02 
Operating Cash Flow Per Share 1.79  1.02 
Free Cash Flow Per Share 0.94  0.64 
Cash Per Share 3.95  4.15 
Capex To Operating Cash Flow 0.48  0.51 
EV To Operating Cash Flow 34.36  36.08 
EV To Free Cash Flow 65.80  69.09 
Price To Operating Cash Flows Ratio 24.32  25.54 
Price To Free Cash Flows Ratio 46.58  48.91 
Cash Ratio 0.90  1.47 
Cash Conversion Cycle 227.52  256.50 
Operating Cash Flow Sales Ratio 0.09  0.10 
Free Cash Flow Operating Cash Flow Ratio 0.52  0.43 
Cash Flow Coverage Ratios 0.09  0.09 
Price Cash Flow Ratio 24.32  25.54 
Cash Flow To Debt Ratio 0.09  0.09 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.